Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
CPNE1 CPN1
Sequence Length (AA) Molecular Weight (Da)
537 59059
Protein Name
Copine-1
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MAHCVTLVQL SISCDHLIDK DIGSKSDPLC VLLQDVGGGS WAELGRTERV
60 70 80 90 100
RNCSSPEFSK TLQLEYRFET VQKLRFGIYD IDNKTPELRD DDFLGGAECS
110 120 130 140 150
LGQIVSSQVL TLPLMLKPGK PAGRGTITVS AQELKDNRVV TMEVEARNLD
160 170 180 190 200
KKDFLGKSDP FLEFFRQGDG KWHLVYRSEV IKNNLNPTWK RFSVPVQHFC
210 220 230 240 250
GGNPSTPIQV QCSDYDSDGS HDLIGTFHTS LAQLQAVPAE FECIHPEKQQ
260 270 280 290 300
KKKSYKNSGT IRVKICRVET EYSFLDYVMG GCQINFTVGV DFTGSNGDPS
310 320 330 340 350
SPDSLHYLSP TGVNEYLMAL WSVGSVVQDY DSDKLFPAFG FGAQVPPDWQ
360 370 380 390 400
VSHEFALNFN PSNPYCAGIQ GIVDAYRQAL PQVRLYGPTN FAPIINHVAR
410 420 430 440 450
FAAQAAHQGT ASQYFMLLLL TDGAVTDVEA TREAVVRASN LPMSVIIVGV
460 470 480 490 500
GGADFEAMEQ LDADGGPLHT RSGQAAARDI VQFVPYRRFQ NAPREALAQT
510 520 530 537
VLAEVPTQLV SYFRAQGWAP LKPLPPSAKD PAQAPQA

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-484 Collapse assay details

Data source: Panorama

Official Gene Symbol
CPNE1
Peptide Sequence
GTITVSAQELK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
125
Peptide End
135
CPTAC ID
CPTAC-484
Peptide Molecular Mass
1,145.6292
Species
Homo sapiens (Human)
Assay Type
Direct MRM
Matrix
cell line lysate pool
Submitting Laboratory
Seoul National University / Korea Institute of Science and Technology and FHCRC
Submitting Lab PI
Youngsoo Kim

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Seoul National University / Korea Institute of Science and Technology. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Seoul National University / Korea Institute of Science and Technology. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
5500 QTRAP (ABSCIEX)
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)
Column Packing
ChromXP C18-CL, 3 um, 120A
Column Dimensions
150 x 0.075 mm
Flow Rate
500 nL / min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y8 (1+) 14.6 5.2 9 14.9 8.6 9.4 20.9 10 13 15 25 15
y7 (1+) 6.8 7.3 9.8 13.5 11.5 11.3 15.1 13.6 15 15 25 15
y6 (1+) 11.9 9.5 8.4 21.3 11.1 9.4 24.4 14.6 12.6 15 25 15
sum 9 6 7.4 14.8 9.1 7.3 17.3 10.9 10.4 15 25 15


Additional Resources and Comments


Assay Details for CPTAC-485 Collapse assay details

Data source: Panorama

Official Gene Symbol
CPNE1
Peptide Sequence
SDPFLEFFR
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
158
Peptide End
166
CPTAC ID
CPTAC-485
Peptide Molecular Mass
1,156.5553
Species
Homo sapiens (Human)
Assay Type
Direct MRM
Matrix
cell line lysate pool
Submitting Laboratory
Seoul National University / Korea Institute of Science and Technology and FHCRC
Submitting Lab PI
Youngsoo Kim

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Seoul National University / Korea Institute of Science and Technology. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Seoul National University / Korea Institute of Science and Technology. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
5500 QTRAP (ABSCIEX)
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C,15N
LC
nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)
Column Packing
ChromXP C18-CL, 3 um, 120A
Column Dimensions
150 x 0.075 mm
Flow Rate
500 nL / min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y6 (1+) 27 6 4.5 37.6 8.7 6.9 46.3 10.6 8.2 15 25 15
y5 (1+) 27.6 6 3.5 36.6 8.8 7.4 45.8 10.7 8.2 15 25 15
y4 (1+) 29.6 6.2 4 39.7 8.5 8.7 49.5 10.5 9.6 15 25 15
sum 25.6 5.5 3.8 36.5 8.5 7.4 44.6 10.1 8.3 15 25 15


Additional Resources and Comments